LL-37 and Thymosin Alpha-1 are both Immune Support peptides, but they're studied for different things. In short, LL-37 is the human cathelicidin antimicrobial peptide studied for immune defense, while Thymosin Alpha-1 is an immune-modulating peptide used clinically in several countries. This page compares the two side by side — what each is researched for, how mature the evidence is, and how they're typically used — so you can see where they overlap and where they differ. It's educational information only, not medical advice, and neither is a substitute for a conversation with a licensed professional.
LL-37 vs Thymosin Alpha-1 at a glance
| LL-37 | Thymosin Alpha-1 | |
|---|---|---|
| Category | Immune Support | Immune Support |
| In short | The human cathelicidin antimicrobial peptide studied for immune defense. | An immune-modulating peptide used clinically in several countries. |
| Researched for | Antimicrobial defense, Wound healing, Immune modulation | Immune modulation, Infection support, Vaccine response studies |
| Research status | Active area of preclinical research. | Human clinical use in several countries; ongoing research. |
| Typically stacked with | — | — |
| Key consideration | At high levels it has been linked to inflammatory conditions in research. Human therapeutic data is limited. | Regulatory status varies by country. Should be used under medical supervision. |
How does LL-37 work?
LL-37 is the active form of the human cathelicidin antimicrobial peptide, a part of the innate immune system. Research covers its antimicrobial activity, roles in wound healing, and immune modulation — though at high levels it has also been linked to inflammatory conditions.
How does Thymosin Alpha-1 work?
Thymosin Alpha-1 is a naturally occurring peptide that helps regulate the immune system, particularly T-cell function. It is used clinically in a number of countries as an immune modulator, including as an adjunct in certain infections and cancers.
LL-37 vs Thymosin Alpha-1: how to choose
Choosing between LL-37 and Thymosin Alpha-1 really comes down to your specific goal — and it's a decision for you and a licensed professional, not something to settle from a web page. LL-37 is most associated with Antimicrobial defense and Wound healing, while Thymosin Alpha-1 leans toward Immune modulation and Infection support. Where they overlap, the practical differences are usually in mechanism and how far the research has actually progressed. Selpho provides no dosing or protocols; if you'd like a research-backed steer for your goals, the free Peptide Advisor is a good starting point.
Frequently asked questions
Both are Immune Support peptides. LL-37 is the human cathelicidin antimicrobial peptide studied for immune defense; Thymosin Alpha-1 is an immune-modulating peptide used clinically in several countries. They're most researched for Antimicrobial defense, Wound healing (LL-37) and Immune modulation, Infection support (Thymosin Alpha-1), respectively.
There's no universal "better" — it depends on your goal, and for most of these compounds robust head-to-head human evidence doesn't exist. The right choice is one made with a licensed professional. Selpho does not rank or prescribe; it offers educational information and a research-backed advisor.
They're in the same category, and combining research compounds is something to approach only with a licensed professional, since interactions and individual context matter. Selpho provides no dosing or protocols.
LL-37: Active area of preclinical research. Thymosin Alpha-1: Human clinical use in several countries; ongoing research.
Not sure which fits your goals?
Describe your situation and Selpho's free AI advisor will suggest research-backed peptides — no signup needed.
Try the Peptide AdvisorThis comparison is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.